What happens to patients when a court halts their compounded tirzepatide program? This is GLP-1 Daily. Today: medication apps under scrutiny, and what to make of Lilly’s ObesityWeek lineup. First, Brazil—and the people caught in the Bolsa Mounjaro suspension.
From Juri News:
The Justice of São Paulo determined the suspension of the applications of manipulative tirzepatida offered free of charge by the City Hall of Urupês, in the interior of São Paulo. The decision affects about 400 patients treated by the municipal program known as “Bolsa Mounjaro” and was motivated by questions about compliance with the norms of the National Health Surveillance Agency (Anvisa). The city appealed, but the request was denied.
Urupês started its free tirzepatide program in February for people with obesity who couldn't afford treatment, especially those waiting for bariatric surgery. It grew from 200 patients to about 400. Now, Juri News reports, a São Paulo court has suspended the injections, and the city's appeal was denied. And that nickname, “Bolsa Mounjaro,” needs unpacking: the city was supplying compounded tirzepatide, not branded Mounjaro. Lilly brought the lawsuit, arguing that repeated purchases of 60- and 63-milligram vials showed large-scale distribution outside Anvisa's compounding rules. That's Lilly's argument; it doesn't establish that every vial was unsafe. The city had already paid more than 268,000 reais by October 27, according to its transparency portal. This was an operating treatment program. Enforcing Anvisa's rules still leaves a very practical question for those 400 patients: who arranges—and pays for—their next prescription?
Obesity Action Coalition writes:
The Obesity Action Coalition (OAC) is sharing new research on what patients want from prescription companion apps for obesity medications. The findings come as the U.S. Food and Drug Administration (FDA) has released new guidance on software used with prescription drugs.
OAC asked 133 adults what they wanted from obesity-medication apps. Eighty-nine percent wanted a clear privacy explanation, and the same share wanted control over what they share. Before you send me another notification, tell me who gets my health information. And 90 percent wanted clear medication instructions. Pretty practical wish list. This is a small survey of patient preferences, though—not evidence that an app improves treatment, and certainly not a verdict from every GLP-1 patient. Still, instructions and privacy both rank right up there. Developers should hear that before adding bells and whistles. OAC also points to new FDA guidance on software used with prescription drugs. Guidance doesn't establish that any particular app has FDA clearance. If an app waves the agency's name around, check exactly what it's claiming.
Asnat Raziel, writing in Dr. Asnat Raziel:
What will Lilly present at ObesityWeek? The American obesity congress runs in Washington from November 14 to 17. Therefore, Lilly is showing several important studies there. The main theme is a question almost every patient asks me. What happens to your weight once the weight-loss phase ends? Lilly will also present body composition data for the Foundayo pill. There is lab research on a new amylin drug, too.
Dr. Asnat Raziel’s preview of Lilly’s ObesityWeek lineup gets to a very practical question: what happens after the weight comes off? SURMOUNT-MAINTAIN compares staying on your tolerated dose, stepping down to five milligrams, and switching to placebo. And the design matters: 441 adults enrolled, but 378 reached randomization after 60 weeks on tirzepatide. Read those maintenance findings as evidence about people who made it through that initial treatment phase—not everyone starting a prescription. That five-milligram arm is the one I’d watch. A lower-dose maintenance option could matter to patients—but insurers shouldn’t turn a study arm into an automatic dose-cut rule. Raziel also flags Foundayo body-composition data and laboratory research on amylin for the November 14–17 meeting. Keep the laboratory label attached to that last one; a conference lineup can make very different stages of evidence sound equally ready for patients.
If you’re finding GLP-1 Daily useful, please subscribe or leave us a review wherever you’re listening. Reviews help other people discover the show, and we appreciate you being here.
Looking ahead, ObesityWeek runs November 14–17 in Washington, with Lilly presentations scheduled on tirzepatide weight maintenance and Foundayo body composition. Links to every story are in the show notes, so take a look at the ones you’d like to explore further. That’s GLP-1 Daily for today—thanks for listening, and we’ll be back next episode. This is a Lantern Podcast.